At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 106 enrolled
Drug / intervention
sunitinibdrug
Likely dose
sunitinib 37.5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A SINGLE-ARM OPEN-LABEL INTERNATIONAL MULTI-CENTER STUDY OF THE EFFICACY AND SAFETY OF SUNITINIB MALATE (SU011248, SUTENT (REGISTERED)) IN PATIENTS WITH PROGRESSIVE ADVANCED METASTATIC WELL-DIFFERENTIATED UNRESECTABLE PANCREATIC NEUROENDOCRINE TUMORS
In Brief
A Phase 4 clinical trial evaluating sunitinib for Well-differentiated Pancreatic Neuroendocrine Tumor. Completed, enrolled 106 participants across 26 sites in 15 countries.
Detailed Summary
The purpose of this study is to confirm the safety and efficacy of sunitinib in subjects with unresectable pancreatic neuroendocrine tumors.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesAustralia, Belgium, China, Czechia, France, Hungary, India, Italy, Japan, Norway, Romania, Slovakia, South Africa, Spain, United States
Collaborators--
Timeline
Phase 4CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedFeb 2012
Enrollment StartJun 2012
Primary CompletionMar 2016
Study CompletionJul 2018
TodayJul 2026
First PostedFeb 3, 2012
Enrollment StartJun 6, 2012
Primary CompletionMar 19, 2016
Study CompletionJul 26, 2018
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 14.4 years ago
Interventions
sunitinibdrug
Sunitinib capsules will be given orally at continuous daily dosing with a starting dose of 37.5 mg. One cycle is equal to 28 days.